BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,363
Mkt Cap
$1.47B
Volume
3.91M
52W High
$11.31
52W Low
$6.00
PE Ratio
-147.36
BCRX Fundamentals
Price
$6.93
Prev Close
$7.03
Open
$7.03
50D MA
$7.22
Beta
1.01
Avg. Volume
6.82M
EPS (Annual)
-$0.43
P/B
-3.78
Rev/Employee
$777,089.66
Loading...
Loading...
News
all
press releases
SG Americas Securities LLC Raises Stake in BioCryst Pharmaceuticals, Inc. $BCRX
SG Americas Securities LLC lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 441.5% during the 2nd quarter, according to the company in its most recent...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen analysts that are presently covering the firm, MarketBeat...
MarketBeat·4d ago
News Placeholder
M&G PLC Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX
M&G PLC acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and...
MarketBeat·9d ago
News Placeholder
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the...
Business Wire·11d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Stake Lifted by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 20.7% during the 2nd quarter, according to the company...
MarketBeat·11d ago
News Placeholder
HC Wainwright Has Positive Estimate for BCRX FY2025 Earnings
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at HC Wainwright increased their FY2025 earnings estimates for BioCryst Pharmaceuticals in a research note issued to...
MarketBeat·15d ago
News Placeholder
Citizens Jmp Has Lowered Expectations for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price
Citizens Jmp reduced their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a "market outperform" rating for the company in a research note on Wednesday...
MarketBeat·17d ago
News Placeholder
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·26d ago
News Placeholder
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·27d ago

Latest BCRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.